Answers are grounded in this paper and cite their sources.
While immunohistochemical biomarkers are widely used to assist pathologic diagnosis, reliable adjunctive markers for high-grade differentiated thyroid carcinoma (HGDTC) and anaplastic thyroid carcinoma (ATC) remain limited. Based on our previous finding that CD109 is associated with the anaplastic transformation of papillary thyroid carcinoma (PTC), we evaluated CD109 expression across follicular cell-derived thyroid carcinomas to assess its utility as an adjunctive immunohistochemical marker. We analyzed 141 thyroid carcinoma cases, including 14 ATC, 29 HGDTC, 63 PTC (22 TERT promoter mutation-positive and 41 mutation-negative), 25 follicular thyroid carcinoma (FTC), and 10 poorly differentiated thyroid carcinoma (PDTC). Among the 29 HGDTC cases, 22 arose from PTC (HGDTC (PTC)) and 7 arose from FTC (HGDTC (FTC)). Using weak or strong cytoplasmic CD109 staining (C1+/C2+) as the cutoff, sensitivity exceeded 90% for HGDTC (PTC) and reached 100% for ATC to differentiate from PDTC, FTC, TERT promoter mutation-negative PTC, and HGDTC (FTC). Restricting positivity to strong cytoplasmic staining (C2+) increased specificity to > 95% for HGDTC (PTC), ATC, and TERT promoter mutation-positive PTC, suggesting that CD109 may be useful as an adjunct biomarker in diagnosing HGDTC (PTC) and ATC. In a parsimonious multivariable analysis, ATC remained associated with C2 + expression after adjustment for age, sex, and Ki-67 labeling index. Overall, strong cytoplasmic CD109 expression is enriched in ATC and may provide supportive evidence for HGDTC (PTC) or anaplastic transformation when interpreted together with morphology.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: